xMPortfolio of Minimal Residual Disease & Monitoring

Our portfolio of tumor-naive and tumor-informed minimal residual disease (MRD) and monitoring assays provides physicians with valuable patient insights to individualize treatment plans.

xM is a finely tuned MRD assay that delivers rapid results from one blood draw to help detect residual disease or recurrence in colorectal cancer.

xM (NeXT Personal® Dx)* is an ultra sensitive, whole genome MRD and monitoring assay that enables detection of ctDNA at very low levels in NSCLC, breast cancer and for IO treatment response monitoring.

*Test by Personalis

xM is a tumor-naive, finely tuned assay


xM was developed using Tempus’ multimodal database and advanced machine learning algorithms to help accurately detect and classify tumor fragments from non-tumor fragments.

Cancer Indications

Stage II-III colorectal cancer patients

Tumor-naive approach

xM is a blood-based assay that can be seamlessly integrated into a patient’s routine blood draw schedule, minimizing the burden to clinical practices.


Binary ctDNA status call (detected/not detected)

image description

xM (NeXT Personal® Dx) is a tumor-informed, ultra-sensitive whole genome assay


xM (NeXT Personal® Dx) is an ultra-sensitive personalized MRD assay, capable of detecting molecular markers at concentrations as low as 4 parts per million (PPM). It utilizes whole genome sequencing to identify up to 1800 somatic variants, filtering out confounding factors such as CHIP and germline variants through a tumor normal matched approach.

Cancer Indications

Stage IA–IIIB NSCLC patients

Stage II–III breast cancer patients

IO monitoring for pan solid tumors

Tumor-informed approach

xM (NeXT Personal® Dx) utilizes a tumor-informed methodology and provides a personalized assessment of residual disease based on information specific to the patient’s tumor DNA.


Binary ctDNA status call (detected/not detected) and quantitative results

Detection of ctDNA may function as an early indicator for recurrent malignancy, prior to being seen on radiographic scans.


xM is effective at detecting colorectal cancer recurrence at a landmark timepoint and over time, which enables providers to make timely management decisions for their patients.2,3

image description


xM (NeXT Personal® Dx) provides clinicians with high confidence in detecting residual disease or recurrence in NSCLC patients who test MRD positive at the landmark and/or longitudinal timepoints, with results predictive of 5-year RFS and overall survival.5,6

image description

Improving your workflows

Tempus offers a variety of options to customize MRD testing for patients.


Place a single MRD order or a series of longitudinal orders, based on a cadence you determine is medically necessary.

image description


We want to make blood draw services as convenient as possible for your patients who are unable to come into typical clinical/hospital settings.

To schedule an appointment, please call 800.739.4137 or utilize the Mobile Phlebotomy Request Form.

image description


Order and view results through our AI-enabled online platform. Paper requisition and EHR ordering are also available.

Access Tempus Hub
image description


view all RESOURCES

    Press Release: Clinical Launch of Tempus’ MRD Testing Portfolio

    Read more

    Abstract: 2024 ASCO® GI Symposium

    Read more

    Abstract: 2024 ASCO® Annual Meeting

    Read more
Financial Assistance

We help provide access to our tests for all patients in financial need.

Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission. 

  • Step 1

    Apply for financial assistance online at access.tempus.com.

  • Step 2

    If approved, you will know immediately about the maximum out-of-pocket cost of your testing.

  • Step 3

    Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

  1. Yoshiaki Nakamura, Kristiyana Kaneva, Christine Lo, et al. Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in resected stage II and III colorectal cancer patients: A subset analysis from the GALAXY study in CIRCULATE-Japan. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2024; Chicago Illinois.
  2. Landmark time point is defined as approximately 4 weeks after surgery in pathological stage II or III colorectal cancer (CRC).
  3. Longitudinal performance characteristics were determined based on landmark and longitudinal use of the assay. Longitudinal use in the study to determine performance characteristics was every 3 months after surgery (not including during adjuvant chemotherapy) until recurrence, death, or 24 months follow-up was reached, whichever occurred first.
  4. Black JRM, Frankell AM, Veeriah S, et al. LBA55. An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer. Ann Oncol. 2023;34(Suppl):S1294-S1294.
  5. Landmark data includes a mixed population of patients who have or have not received adjuvant therapy up to this time point (within 120 days post-surgery in this study).
  6. Longitudinal data refers to MRD tests after surgery, involving patients that have received at least two ctDNA / MRD test results.

This is data-driven precision medicine

Stay up to date on important product information and learn more about ordering.